Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03YJW
|
|||
Former ID |
DIB014335
|
|||
Drug Name |
Fus-1 tumor suppressor gene therapy
|
|||
Synonyms |
Fus-1 tumor suppres; INGN-401; P53 bystander effector, Introgen; DOTAP:chol-TUSC2; FUS1-DOTAP:cholesterol; Fus-1 tumor suppressor gene therapy - nanoparticle formulation (cancer); Fus-1 tumor suppressor gene therapy-nanoparticle formulation (cancer), MD Anderson
Click to Show/Hide
|
|||
Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 1/2 | [1] | |
Company |
Genprex
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tumor suppressor candidate 2 (TUSC2) | Target Info | Suppressor | [2] |
WikiPathways | miR-targeted genes in muscle cell - TarBase | |||
miR-targeted genes in lymphocytes - TarBase | ||||
miR-targeted genes in leukocytes - TarBase |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018766) | |||
REF 2 | INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D. 2007;8(3):176-87. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.